Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04325321 · ClinicalTrials.gov registry record · NA
The Broken Heart Study II (BHS-II)
A NA study of Takotsubo Cardiomyopathy, sponsored by The Miriam Hospital.
- Active
- Registry status
- NA
- Development phase
- 66
- Enrollment target
- 1
- Study location
NCT04325321 is a NA study of Takotsubo Cardiomyopathy that is active but no longer recruiting, run by The Miriam Hospital. The registered enrollment target is 66 participants, below the 508-participant average among 3 other Takotsubo Cardiomyopathy trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04325321, a NA study of Takotsubo Cardiomyopathy, is active but no longer recruiting, sponsored by The Miriam Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 66 participants
- Enrollment target
- 1
- Study location
Study Summary
The goals of this study are as follows: 1. To rigorously establish and characterize heterogeneity in the pathophysiology of Takotsubo Syndrome (TS). 2. To rigorously test the contribution of TS triggering events and mental stress responsiveness to 1-year prognosis after TS event.
Conditions Studied
Interventions
- OTHER Stress reactivity test
Study Locations (1)
Rhode Island
- The Miriam Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2020-09-02 |
| Est. Completion | 2026-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04325321
The ClinicalTrials.gov registry entry for NCT04325321 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 508-participant average among 3 other Takotsubo Cardiomyopathy trials with a reported enrollment target (87% lower). The listed sponsor is The Miriam Hospital, which has 136 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Takotsubo Cardiomyopathy appearing as the primary indexed condition, and to 1 intervention - of which Stress reactivity test is the first listed.
NCT04325321 reports 1 study location spanning 1 distinct geographic area - top geographies include Rhode Island.
Frequently Asked Questions
What is clinical trial NCT04325321 about?
NCT04325321 is a clinical study titled "The Broken Heart Study II (BHS-II)". The goals of this study are as follows: 1. To rigorously establish and characterize heterogeneity in the pathophysiology of Takotsubo Syndrome (TS). 2. To rigorously test the contribution of TS triggering events and mental stress responsiveness to 1-year prognosis after TS event.
What is the current status of trial NCT04325321?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 66 participants. The study started on 2020-09-02. Estimated completion is 2026-02.
What conditions does trial NCT04325321 study?
This clinical trial studies the following conditions: Takotsubo Cardiomyopathy.
What interventions are being tested in trial NCT04325321?
The interventions under investigation include: Stress reactivity test (OTHER).
Who is sponsoring clinical trial NCT04325321?
This trial is sponsored by The Miriam Hospital, which has 136 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04325321 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Takotsubo Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.